Lilly’s Weight-Loss Franchise Reshapes Pharma’s Order — and Its Own Forecast
Eli Lilly’s Zepbound and Mounjaro surge past estimates, lifting 2026 revenue guidance to $87 billion. What the new forecast signals about GLP-1 dominance.
Eli Lilly’s Zepbound and Mounjaro surge past estimates, lifting 2026 revenue guidance to $87 billion. What the new forecast signals about GLP-1 dominance.
McDonald’s beat Q2 earnings and named a new U.S. head, but its stock is down 11% this year. What the leadership change signals for investors, franchisees, and the fast-food value war.
UEFA and Concacaf blocked FIFA’s plan to sell 20% of World Cup commercial rights, exposing deep unease about private equity in football governance.
Incoming Best Buy CEO Jason Bonfig tells CNBC that smaller stores are central to expanding the retailer’s reach and improving customer experience. Here’s what the strategy signals for the sector.
Consumer companies are staying private longer, using secondary markets and patient capital to buy time. Here’s who wins, who loses, and what the IPO road’s decline means.
Rivian trimmed its 2026 spending plan and narrowed its full-year loss forecast in Q2 results. Here is who gains, who loses, and what it signals for EVs.
Starbucks posts fourth consecutive quarter of same-store sales growth under CEO Brian Niccol and raises full-year outlook, signaling the coffee giant’s operational overhaul is gaining traction.
Nike China sales fell 30% as domestic brands like Anta and Li-Ning capture young consumers. Analysis of market shifts, second-order effects, and what comes next.
Coca-Cola tops Q2 earnings estimates and hikes full-year outlook, with stock up 19% YTD. Analysis of consumer resilience, market context, and what the beat means for the sector.
Ford expands accessory business to boost profits, targeting the $53 billion US aftermarket with ‘Nike shoe drop’ moments for personalized vehicles.
Copyright © 2026 | Celloraa Editorial Team | Editorial Policy | Privacy Policy | Disclaimer